Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with overall response rates ranging between 34% and 43%.
Intercellular communication between tumor cells and cancer-associated fibroblasts (CAFs) plays a key role in tumorigenesis and progression, and CAFs generate an extracellular matrix that provides a repository for factors that promote cancer progression. Alpha Beta Therapeutics Inc. researchers aimed to investigate the mechanisms by which CAFs facilitate tumor initiation and tumorigenesis of pancreatic cancer.
Dewpoint Therapeutics Inc. has nominated a second development candidate, DPTX-3496. The oral, small-molecule condensate modulator targets β-catenin to address Wnt-driven colorectal cancer, triple-negative breast cancer and non-small-cell lung cancer. IND-enabling studies have commenced, with an IND filing planned in the second half of this year.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. and Tianjin Synnocare Biomedical Technology Co. Ltd. have jointly developed new N-myristoyltransferase 1 (NMT1) inhibitors reported to be useful for the treatment of cancer, malaria, leishmaniasis, rhinovirus and HIV infections.
Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
A University of California patent describes new inhibitors of GTPase KRAS, particularly KRAS G12D mutant, reported to be useful for the treatment of cancer.
Seed Therapeutics Inc.’s ST-01156 has been awarded orphan drug designation for the treatment of Ewing sarcoma as well as rare pediatric disease designation by the FDA.
Scientists at the University of Wisconsin Madison and Dana-Farber Cancer Institute recently presented preclinical data for the radiopharmaceutical therapy candidate [177Lu]PNT-6555.
RSS
